Gold Hammered on Open to OpEx Perfection
If you ever wonder sometimes why some things happen in this life when the data is screaming that the opposite should be occurring, standing around in a state of confusion and railing against the unfairness of it all makes for a pretty futile afternoon.Â If you’d watched gold trade this week you had to know there was something out there that was causing the market players to dump gold on the U.S. open in order to push the price towards a certain point.
As zerohedge has been pointing out all week, someone wanted gold stuffed back into a particular range and did so with impunity on the open every day this week until the desired effect was achieved.Â What was that outcome?Â A perfect close on the GLD ETF for the option-writers, that’s what.Â Today was a perfect example of how option pain theory is applied in practice.
The sad part is that on the same day JPMorgan is slapped on the wrist 417 million times for stealing trillions in selling crappy mortgage bonds they execute a perfect close in the gold pits to inflict maximum pain on those who bought puts and calls from them.Â It is almost like they are rubbing our noses in it.Â Fine us for stealing from you?Â Fine, we’ll just make it back setting prices on Options Expiration day and pocketing all of those premiums.Â Suckers!
Option Pain number for GLD this month was $166.Â The close today?Â $165.88.Â If they really wanted to rub it in they could have closed it at $165.99, but that would have been gauche.
Currency Articles - Oct 23, 2015 9:50 - 0 Comments
More In Currency Articles
- Unemployment Level Suggests UK Is Ready For Rate Hike But Speculation Still Says No
- GBP/EUR Sinks To Month Low As Concerns On VW Continue
Gold and Oil News - Oct 7, 2014 17:44 - 0 Comments
More In Gold and Oil News
- Gold Falls But Higher Prices May Be On The Horizon
- Gold Prices Spike Higher On Increased Israel Tension
Shares and Markets - Nov 9, 2015 13:55 - 0 Comments
More In Shares and Markets
- WANdisco Share Price When Big Data is Booming
- Glaxosmithkline Share Price Rebound Halts On Slower Sales